Skip to Content

Rule

New Animal Drugs; Cefpodoxime; Meloxicam

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Final rule; technical amendment.

SUMMARY:

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval actions for new animal drug Start Printed Page 5714applications (NADAs) and abbreviated new animal drug applications (ANADAs) during December 2012. FDA is also informing the public of the availability of summaries of the basis of approval and of environmental review documents, where applicable.

DATES:

This rule is effective January 28, 2013.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9019, george.haibel@fda.hhs.gov.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

FDA is amending the animal drug regulations to reflect approval actions for several original ANADAs during December 2012, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the Internet may obtain these documents at the Center for Veterinary Medicine FOIA Electronic Reading Room: http://www.fda.gov/​AboutFDA/​CentersOffices/​OfficeofFoods/​CVM/​CVMFOIAElectronicReadingRoom/​default.htm.

Table 1—Original ANADAs Approved During December 2012

NADA/ANADASponsorNew animal drug product nameAction21 CFR sectionFOIA summaryNEPA review
200-485Accord Healthcare, Inc., 1009 Slater Rd., suite 210-B, Durham, NC 27703Meloxicam InjectionOriginal approval as a generic copy of NADA 141-219522.1367yesCE1
200-491Norbrook Laboratories, Ltd., Station Works, Newry BT35 6JP, Northern IrelandLOXICOM (meloxicam) Solution for InjectionOriginal approval as a generic copy of NADA 141-219522.1367yesCE1
200-543Putney, Inc., 400 Congress St., suite 200, Portland, ME 04101Cefpodoxime Proxetil TabletsOriginal approval as a generic copy of NADA 141-232520.370yesCE1
1 The Agency has determined under 21 CFR 25.33 that this action is categorically excluded (CE) from the requirement to submit an environmental assessment or an environmental impact statement because it is of a type that does not individually or cumulatively have a significant effect on the human environment.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

Start List of Subjects

List of Subjects

and 522

End List of Subjects

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 520, and 522 are amended as follows:

Start Part

PART 510—NEW ANIMAL DRUGS

End Part Start Amendment Part

1. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

End Authority
[Amended]

2. In § 510.600, in the table in paragraph (c)(1), alphabetically add an entry for “Accord Healthcare, Inc.” and revise the entry for “Jurox Pty. Ltd.”; and in the table in paragraph (c)(2), numerically add an entry for “016729” and revise the entry for “049480” to read as follows:

(1) * * *

Firm name and addressDrug labeler code
*    *    *    *    *
Accord Healthcare, Inc., 1009 Slater Rd., suite 210-B, Durham, NC 27703016729
*    *    *    *    *
Jurox Pty. Ltd., 85 Gardiner St., Rutherford, NSW 2320, Australia049480
*    *    *    *    *

(2) * * *

Drug labeler codeFirm name and address
*    *    *    *    *
016729Accord Healthcare, Inc., 1009 Slater Rd., suite 210-B, Durham, NC 27703
*    *    *    *    *
049480Jurox Pty. Ltd., 85 Gardiner St., Rutherford, NSW 2320, Australia
*    *    *    *    *
Start Part

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

3. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority
[Amended]
Start Amendment Part

4. In paragraph (b) of § 520.370, remove “No. 000009” and in its place add “Nos. 000009 and 026637”.

End Amendment Part Start Part

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

5. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority
Start Printed Page 5715
[Amended]
Start Amendment Part

6. In paragraph (b) of § 522.1367, remove “No. 000010” and in its place add “Nos. 000010, 016729, and 055529”.

End Amendment Part Start Signature

Dated: January 22, 2013.

Bernadette Dunham,

Director, Center for Veterinary Medicine.

End Signature End Supplemental Information

[FR Doc. 2013-01647 Filed 1-25-13; 8:45 am]

BILLING CODE 4160-01-P